ML virtual screening of about 360K compounds yields 24/256 and 47/128 in vitro SARS-CoV-2 hits
Source check: Needs source check. Not independent scientific confirmation.
Finding: 346 model-selected compounds tested: 9.4% hit rate in a pseudotyped particle entry assay and 37% in an RdRp assay; top potencies about 1 uM. Hits are enzyme/entry assay activity; no antiviral efficacy in vivo; models' AUC-ROC modest (>0.72/>0.79).
Technology: QSAR and virus-selective ML models trained on viral genomes and antiviral structures
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- ML models ranked the library; selected compounds were assayed.
- Test and result
- 346 model-selected compounds tested: 9.4% hit rate in a pseudotyped particle entry assay and 37% in an RdRp assay; top potencies about 1 uM.
- Limitation / still unknown
- Hits are enzyme/entry assay activity; no antiviral efficacy in vivo; models' AUC-ROC modest (>0.72/>0.79).
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:%2210.1038/s42004-025-01583-2%22&resultType=core&format=json
Needs source check · editorial details
The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 17 Nov 2026. Review scope: Abstract and metadata via Europe PMC; full text not read.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.